InflaRx N.V. (NASDAQ:IFRX) Receives Average Rating of “Moderate Buy” from Analysts

InflaRx N.V. (NASDAQ:IFRX) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $7.50.

Several research firms recently commented on IFRX. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of InflaRx in a research note on Tuesday, December 30th. Guggenheim raised their price objective on shares of InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a report on Monday, November 10th. Raymond James Financial reissued an “outperform” rating on shares of InflaRx in a report on Wednesday, December 31st. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down from $5.00) on shares of InflaRx in a report on Wednesday, December 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a report on Monday, December 29th.

Institutional Trading of InflaRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IFRX. Bank of America Corp DE acquired a new position in shares of InflaRx in the 3rd quarter valued at $3,316,000. Susquehanna International Group LLP acquired a new stake in InflaRx during the 3rd quarter worth $190,000. Insigneo Advisory Services LLC purchased a new stake in InflaRx in the fourth quarter valued at $61,000. HRT Financial LP acquired a new position in InflaRx in the fourth quarter valued at $47,000. Finally, Squarepoint Ops LLC grew its holdings in shares of InflaRx by 72.0% during the fourth quarter. Squarepoint Ops LLC now owns 324,349 shares of the company’s stock worth $328,000 after purchasing an additional 135,826 shares during the last quarter. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Stock Down 1.2%

InflaRx stock opened at $0.92 on Monday. InflaRx has a 52-week low of $0.71 and a 52-week high of $1.94. The firm has a market cap of $61.76 million, a PE ratio of -1.35 and a beta of 1.48. The company’s 50 day moving average is $0.97 and its two-hundred day moving average is $1.16.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.